Klaria Pharma Holding AB (FRA:6FN) PB Ratio: (As of Jun. 30, 2026)


FRA:6FN Klaria Pharma Holding AB FRA:6FN
28 GF Score
Price €0.06
GF Value €0.03
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Klaria Pharma Holding AB PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-30), Klaria Pharma Holding AB's share price is €0.0619. Klaria Pharma Holding AB's Book Value per Share for the quarter that ended in Mar. 2026 was €-0.01. Hence, Klaria Pharma Holding AB's PB Ratio of today is .

The historical rank and industry rank for Klaria Pharma Holding AB's PB Ratio or its related term are showing as below:

During the past 12 years, Klaria Pharma Holding AB's highest PB Ratio was 107.67. The lowest was 0.60. And the median was 2.49.

FRA:6FN's PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.845
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Klaria Pharma Holding AB's average Book Value Per Share Growth Rate was -863.60% per year.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Klaria Pharma Holding AB was 1118.90% per year. The lowest was -73.80% per year. And the median was -22.95% per year.

Back to Basics: PB Ratio


Klaria Pharma Holding AB  (FRA:6FN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Klaria Pharma Holding AB PB Ratio Related Terms


Klaria Pharma Holding AB PB Ratio Historical Data

* Premium members only.

The historical data trend for Klaria Pharma Holding AB's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klaria Pharma Holding AB PB Ratio Chart

Klaria Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.01 0.99 0.88 12.60 0.00

Klaria Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 112.50 0.00 20.80 0.00 0.00

FRA:6FN vs ZTS, UTHR: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Klaria Pharma Holding AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Klaria Pharma Holding AB PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Klaria Pharma Holding AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Klaria Pharma Holding AB's PB Ratio falls into.


FRA:6FN
28GF Score
Klaria Pharma Holding AB FRA:6FN
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Klaria Pharma Holding AB PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Klaria Pharma Holding AB's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=0.0619/-0.008
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?

Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued. The current stock price of €0.06 is trading 106.3% above its estimated GF Value™ of €0.03. GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.

Key valuation signals for FRA:6FN:

  • PB Ratio:
  • GF Value™: €0.03 vs. price of €0.06 (106.3% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Klaria Pharma Holding AB Business Description

Other Exchanges KLAR:Sweden
Address Virdings Alle 2, Uppsala, CHE, 754 50
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
28GF Score

Get the complete analysis for FRA:6FN

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price
€0.03
GF Value